Efavirenz pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention

Post Date: 
2015-06-16
Publication: 
Clinical Infectious Diseases
Summary: 
Background: Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeutic concentrations of antiretroviral drugs. We studied the interaction of efavirenz with daily rifapentine and isoniazid in human immunodeficiency virus (HIV)-infected individuals receiving a 4-week regimen to prevent tuberculosis.
 
Methods: Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of concomitant therapy. Efavirenz apparent oral clearance was estimated and the geometric mean ratio (GMR) of values before and during rifapentine and isoniazid was calculated. HIV type 1 (HIV-1) RNA was measured at baseline and week 8.
Citation: 
Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson Cam, Kim P, Fletcher CV on behalf of the ACTG A5279 Study Team. Efavirenz pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;16 Jun. pii: civ464.
Collaborators: 
  • University of Nebraska Medical Center, Omaha, NE
  • Harvard School of Public Health, Boston, MA
  • University of the Witwatersrand, Johannesburg, South Africa
  • Chiang Mai University, Thailand
  • University of the Witwatersrand and Baragwanath Hospital, Soweto, South Africa
  • University of California, San Diego, San Diego, CA
  • NIH/NIAID, Bethesda, MD